These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7021451)

  • 21. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.
    Tariot PN; Schneider L; Katz IR; Mintzer JE; Street J; Copenhaver M; Williams-Hughes C
    Am J Geriatr Psychiatry; 2006 Sep; 14(9):767-76. PubMed ID: 16905684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients.
    Yasui-Furukori N; Kondo T; Suzuki A; Mihara K; Kaneko S; Otani K
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Apr; 26(3):575-8. PubMed ID: 11999910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Open clinical trial with haloperidol decanoate in patients with psychotic disorders].
    Ellerman LA
    Acta Psiquiatr Psicol Am Lat; 1987 Jun; 33(2):157-62. PubMed ID: 3321918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Open study with bromperidol in hospitalized chronic schizophrenic patients.
    Hermans W
    Acta Psychiatr Belg; 1978; 78(1):89-95. PubMed ID: 347883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-induced parkinsonism following chronic methamphetamine use by a patient on haloperidol decanoate.
    Matthew BJ; Gedzior JS
    Int J Psychiatry Med; 2015; 50(4):405-11. PubMed ID: 26526398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind comparison of bromperidol and haloperidol in newly admitted schizophrenic patients.
    Brannen JO; McEvoy JP; Wilson WH; Petrie WM; Ban TA; Berney SA; Schaffer JD
    Pharmacopsychiatria; 1981 Jul; 14(4):139-40. PubMed ID: 6116246
    [No Abstract]   [Full Text] [Related]  

  • 27. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia.
    Lublin H; Gerlach J; Hagert U; Meidahl B; Mølbjerg C; Pedersen V; Rendtorff C; Tolvanen E
    Eur Neuropsychopharmacol; 1991 Dec; 1(4):541-8. PubMed ID: 1822319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The characteristics of side-effects of bromperidol in schizophrenic patients.
    Yasui-Furukori N; Kondo T; Ishida M; Tanaka O; Mihara K; Kaneko S; Otani K
    Psychiatry Clin Neurosci; 2002 Feb; 56(1):103-6. PubMed ID: 11929578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroleptic potency of bromperidol.
    Haase HJ; Kaumeier S; Schwarz H; Gundel A; Linde OK; Maetz H; Scheel R; Stripf A; Stripf L
    Acta Psychiatr Belg; 1978; 78(1):83-8. PubMed ID: 347882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The initial US clinical experience in the management of schizophrenic patients with bromperidol.
    Gardner E
    Acta Psychiatr Belg; 1978; 78(1):134-46. PubMed ID: 347876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Side effects during long-term treatment with depot antipsychotic medication.
    Cookson JC
    Clin Neuropharmacol; 1991; 14 Suppl 2():S24-30; discussion S30-2. PubMed ID: 1751940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders.
    Mendlewicz J; de Bleeker E; Cosyns P; Deleu G; Lotstra F; Masson A; Mertens C; Parent M; Peuskens J; Suy E
    Acta Psychiatr Scand Suppl; 1990; 358():138-41. PubMed ID: 1978474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment with bromperidol in schizophrenic patients].
    Ellerman LA
    Acta Psiquiatr Psicol Am Lat; 1989; 35(1-2):23-30. PubMed ID: 2634329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial.
    Heck AH; Haffmans PM; de Groot IW; Hoencamp E
    Schizophr Res; 2000 Dec; 46(2-3):97-105. PubMed ID: 11120421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of the clinical effects of bromperidol, a new butyrophenone derivative, and haloperidol on schizophrenia using a double-blind technique.
    Itoh H
    Psychopharmacol Bull; 1985; 21(1):120-2. PubMed ID: 3885289
    [No Abstract]   [Full Text] [Related]  

  • 36. Development of tolerance to the therapeutic effect of amantadine on akathisia.
    Zubenko GS; Barreira P; Lipinski JF
    J Clin Psychopharmacol; 1984 Aug; 4(4):218-20. PubMed ID: 6470196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Involvement of cytochromeP4503A4 in the metabolism of haloperidol and bromperidol].
    Furukori H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Feb; 18(1):9-14. PubMed ID: 9592806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Chronic treatment of schizophrenia with injectable bromperidol decanoate].
    Suárez Richards M
    Acta Psiquiatr Psicol Am Lat; 1985 Sep; 31(3):222-8. PubMed ID: 2870608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A double-blind comparative multicentre study of remoxipride and haloperidol in schizophrenia.
    Lindström LH; Wieselgren IM; Struwe G; Kristjansson E; Akselson S; Arthur H; Andersen T; Lindgren S; Norman O; Naimell L
    Acta Psychiatr Scand Suppl; 1990; 358():130-5. PubMed ID: 1978472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Haloperidol decanoate. Results of an open-ended multicentric study in chronic psychotic states].
    Lemperiere T; Ropert R; Leger JM; Alexandre JY; Clerc G; Darondel A; Delaunay J; Delteil P; Malauzat D; Raynaud J
    Encephale; 1984; 10(5):217-22. PubMed ID: 6519017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.